Updating results

Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplantation

In development [GID-IPG10149] Expected publication date: TBC

Interventional procedures guidance In development

Percutaneous closure device to repair a paravalvular leak around a replaced mitral or aortic valve

In development [GID-IPG10150] Expected publication date: TBC

Interventional procedures guidance In development

Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Technology appraisal guidance In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 18 March 2021

NICE guideline In development

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

In development [GID-TA10202] Expected publication date: TBC

Technology appraisal guidance In development

Ivosidenib for treating relapsed or refractory acute myeloid leukaemia ID1548

In development [GID-TA10416] Expected publication date: 28 April 2021

Technology appraisal guidance In development

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

In development [GID-TA10429] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]

In development [GID-TA10399] Expected publication date: TBC

Technology appraisal guidance In development

Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Technology appraisal guidance In development

Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: TBC

Technology appraisal guidance In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 10 November 2020

Antimicrobial prescribing guideline In development

Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 10 June 2020

Technology appraisal guidance In development

DHT pilot: Lifelight First for monitoring vital signs

In development [GID-MT532] Expected publication date: TBC

Medical technologies guidance In development

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

In development [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance In development

Abortion care

In development [GID-QS10084] Expected publication date: 18 August 2020

Quality standard In development

Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

In development [GID-TA10546] Expected publication date: TBC

Technology appraisal guidance In development

Permanent His-bundle pacemaker implantation for heart failure

In development [GID-IPG10145] Expected publication date: TBC

Interventional procedures guidance In development

Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury

In development [GID-IPG10146] Expected publication date: TBC

Interventional procedures guidance In development

Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids

In development [GID-IPG10147] Expected publication date: TBC

Interventional procedures guidance In development

Repetitive short pulse transscleral cyclophotocoagulation for glaucoma

In development [GID-IPG10148] Expected publication date: TBC

Interventional procedures guidance In development

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 26 August 2020

Diagnostics guidance In development

Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

In development [GID-TA10221] Expected publication date: TBC

Technology appraisal guidance In development

Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 21 October 2020

NICE guideline In development

Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer - capecitabine [ID389]

In development [GID-TAG394] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (advanced and metastatic) - temozolomide [ID316]

In development [GID-TAG401] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for previously treated metastatic colorectal cancer [ID1030]

In development [GID-TA10138] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

In development [GID-TA10140] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

In development [GID-TA10144] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

In development [GID-TAG406] Expected publication date: TBC

Technology appraisal guidance In development

NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)

In development [GID-TA10183] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating recurrent glioblastoma [ID998]

In development [GID-TA10126] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (primary-progressive) - fingolimod [ID62]

In development [GID-TAG221] Expected publication date: TBC

Technology appraisal guidance In development

Constipation (opioid induced) - lubiprostone [ID646]

In development [GID-TAG367] Expected publication date: 01 October 2014

Technology appraisal guidance In development

Inpatient mental health settings

In development [GID-SGWAVE0701] Expected publication date: TBC

Safe staffing guideline In development

Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]

In development [GID-TAG431] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

In development [GID-TAG363] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

In development [GID-TAG425] Expected publication date: TBC

Technology appraisal guidance In development

Pulmonary arterial hypertension (adults) - drugs [ID12]

In development [GID-TAG382] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]

In development [GID-TAG444] Expected publication date: TBC

Technology appraisal guidance In development

Community nursing care settings

In development [GID-SGWAVE0700] Expected publication date: TBC

Safe staffing guideline In development

Breast cancer - intensity modulated radiotherapy [ID16]

In development [GID-TAG390] Expected publication date: TBC

Technology appraisal guidance In development

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

In development [GID-TAG393] Expected publication date: TBC

Technology appraisal guidance In development

Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Technology appraisal guidance In development

Management and organisational approaches to safe staffing

In development [GID-SGWAVE0761] Expected publication date: TBC

Safe staffing guideline In development

T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

In development [GID-TAG433] Expected publication date: TBC

Technology appraisal guidance In development